Joseph R. Berger, MD, reports on several significant papers presented at ECTRIMS 2024 on neuromyelitis optica spectrum disorder (NMOSD). A noteworthy study from China identified four peripheral inflammatory biomarkers that could predict disease relapse within a year. Additionally, a prominent Harvard study examined treatment outcomes in 107 patients with NMOSD, primarily aquaporin-4–positive women.
This research compared traditional therapies like rituximab and azathioprine with newer treatments such as satralizumab and eculizumab. The older drugs showed high failure rates, whereas the newer medications demonstrated much lower relapse rates and hospitalizations. The findings suggest that these newer treatments should be prioritized due to their higher efficacy and safety profiles.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ECTRIMS 2024: New Biomarkers and Real-World Data on Treatments for NMOSD - Medscape - Sep 26, 2024.
Comments